Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia
Authors:
Open Access
- 2 May 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1394001
Abstract
Introduction: Biomarkers capable of reflecting disease onset and short- and long-term therapeutic effects in individuals with spinal muscular atrophy (SMA) are still an unmet need and phosphorylated neurofilament heavy chain (pNF-H) holds significant promise.Methods: We conducted a longitudinal prospective study to evaluate pNF-H levels in the cerebrospinal fluid (CSF) and plasma of 29 individuals with childhood-onset SMA treated with Nuinersen (SMA type 1: n = 6, 2: n = 17, 3: n = 6). pNF-H levels before and during treatment were compared with the levels of controls (n = 22), patients with Duchenne muscular dystrophy (n = 17), myotonic dystrophy type 1 (n = 11), untreated SMA individuals with chronic type 3 disease (n = 8), and children with presymptomatic SMA (n = 3).Results: SMA type 1 showed the highest mean CSF pNF-H levels before treatment initiation. All Nusinersen-treated individuals (types 1, 2, and 3) showed significantly elevated mean baseline CSF pNF-H compared to controls, which inversely correlated with age at disease onset, age at first dose, disease duration and the initial CHOP INTEND result (SMA type 1 and 2). During 22 months of treatment, CSF pNF-H levels declined during loading doses, stabilizing at reduced levels from the initial maintenance dose in all individuals. Baseline plasma pNF-H levels in type 1 and 2 SMA were significantly increased compared to other cohorts and decreased notably in type 1 after 2 months of treatment and type 2 after 14 months. Conversely, SMA type 3, characterized by lower baseline pNF-H levels, did not show significant fluctuations in plasma pNF-H levels after 14 months of treatment.Conclusion: Our findings suggest that CSF pNF-H levels in untreated SMA individuals are significantly higher than in controls and that monitoring of CSF pNF-H levels may serve as an indicator of rapid short-term treatment response in childhood-onset SMA individuals, irrespective of the subtype of the disease, while also suggesting its potential for assessing long-term suppression of neurodegeneration. Plasma pNF-H may serve as an appropriate outcome measure for disease progression and/or response to treatment in types 1 and 2 but not in type 3. Presymptomatic infants with SMA may show elevated pNF-H levels, confirming early neuronal degeneration.Keywords
This publication has 21 references indexed in Scilit:
- New therapies for spinal muscular atrophy: where we stand and what is nextEuropean Journal of Pediatrics, 2023
- Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 monthsAnnals of Clinical and Translational Neurology, 2022
- Nusinersen: A Review in 5q Spinal Muscular AtrophyCNS Drugs, 2021
- The altered expression of neurofilament in mouse models and patients with spinal muscular atrophyAnnals of Clinical and Translational Neurology, 2021
- Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studyNeuromuscular Disorders, 2019
- Neurofilament as a potential biomarker for spinal muscular atrophyAnnals of Clinical and Translational Neurology, 2019
- Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes2018
- An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)Human Mutation, 2000
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995
- International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)Neuromuscular Disorders, 1992